• Achievement of a strong operating margin of 12.5%, reflecting the significant improvement in industrial margins in Theradiag’s two businesses and the cessation of activities in the United States
• Cash flow controlled at €5.7 million as of June 30, 2023 and increasing in Q2 2023
Croissy-Beaubourg, September 18, 2023, 7:30 a.m. CEST – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, today presents its half-year results as of June 30, 2023 approved by the Board of Directors. administration of September 14, 2023.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]